Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: A randomised clinical trial

HIP International

Volumn 24, Issue 1, 2014, Pages 63-68

  Hourlier, Hervé ^a   Fennema, Peter ^b  

^a Department of Orthopaedic Surgery Polyclinique de la Thiérache ^*  (France)

^b AMR Advanced Medical Research   (Switzerland)

Author keywords

Blood transfusion; Randomised controlled trial; Total hip replacement; Tranexamic acid

Indexed keywords

FONDAPARINUX; HEMOGLOBIN; IRON; PLACEBO; RIVAROXABAN; TINZAPARIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK; SINGLE DRUG DOSE; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; DOSE RESPONSE; EPIDEMIOLOGY; FRANCE; HIP ARTHROPLASTY; INTRAOPERATIVE PERIOD; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UTILIZATION;

AGED; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; INTRAOPERATIVE PERIOD; MALE; MORBIDITY; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84896270794     PISSN: 11207000     EISSN: None     Source Type: Journal    
DOI: 10.5301/hipint.5000090     Document Type: Article

References (20)

1. Goodnough LT. Risks of blood transfusion. Anaesthesiol Clin N Am. 2005;23(2):241-52.
2. Schreiber GB, Buch MP, Kleinmann SP, Korelitz JJ. The risk of transfusion-transmitted viral infections: the Retrovirus Epidemiology Donor Study. N Eng J Med. 1996;334(26):1685-90.
3. Biedler AE, Schneider SO, Seyfert U, et al. Impact of alloantigens and storage-associated factors on stimulated cytokine response in an in vitro model of blood transfusion. Anaesthesiology. 2002;97(5):1102-9.
4. Shakur H, Roberts I, Bautista R, et al. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
5. Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005; 76(3):314-9.
6. Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010;18(3):132-8.
7. Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011;93(1): 39-46.
8. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344: e3054.
9. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; CD001886.
10. Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand. 2000;71:250-4.
11. Claeys MA, Vermeersch N, Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg 2007;107:397-401.
12. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006;105:1034-46.
13. Hourlier H, Fennema P, Line B. A novel blood-saving plan for less-invasive primary total hip replacement. Orthopedics 2008;31(12 Suppl 2). pii: orthosupersite.com/view. asp?rID=37188.
14. Hourlier H. A modified direct lateral minimally invasive approach to the hip. Surgical technique and early results. J Bone Joint Surg Br 2006;88:61.
15. Gross JB. Estimating allowable blood loss: Corrected for dilution. Anesthesiology 1983;58:277-80.
16. Gilcher RO, Belcher AJ. Predeposit programs. In: Sander G, Silvergleid AJ, eds. Autologous transfusion. Arlington, VA: American Association of Blood Banks, 1983;1.
17. Therapeutic Goods Administration. Australian public assessment report for tranexamic acid. Proprietary product name: Cyklokapron. Sponsor: Pfizer Australia Pty Ltd. Woden, ACT: TGA, 2010;84-102.
18. Gill JB, Rosenstein A. The use of antifibrinolytic agents in total hip arthroplasty: A meta-analysis. J Arthroplasty 2006; 21:869-73.
19. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. Thromb Res 2009; 123:687-96.
20. Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res 2013;471:150-4.